<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02363075</url>
  </required_header>
  <id_info>
    <org_study_id>P110501</org_study_id>
    <nct_id>NCT02363075</nct_id>
  </id_info>
  <brief_title>Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia</brief_title>
  <acronym>DXA</acronym>
  <official_title>A Study Evaluating Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia. A Phase III Double-blind Randomized Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to estimate the efficiency at 3 months of dexamfetamine&#xD;
      sulphate on the MFI 20 scale in severe fatigue of patients with stabilized gliomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Quality of life of patients with stabilized gliomas is often impacted by a severe physical&#xD;
      and psychological fatigue resulting from both tumor and side effects of treatments.&#xD;
&#xD;
      It is a randomized double blind Placebo-Controlled Trial evaluating the effect of&#xD;
      dexamfetamine sulphate on severe fatigue in glioma patients. Half of the participants will&#xD;
      receive dexamfetamine sulphate and the other half will receive a placebo. Neither the&#xD;
      participant nor the study doctor will know what group they are in.&#xD;
&#xD;
      The main objective is to assess the impact at 3 months of dexamfetamine sulphate in patients&#xD;
      suffering from a RANO stable or responsive glioma complaining of a severe fatigue (quantified&#xD;
      by the Multidimensional Fatigue inventory - MFI 20 scale).&#xD;
&#xD;
      The secondary objectives include: evaluation of side effects, quality of life, cognitive&#xD;
      functions, depression, variation in time of both fatigue scales MFI 20 and VAS.&#xD;
&#xD;
      58 patients will be included. In patients complaining of severe asthenia, with a non&#xD;
      progressive neuro-oncological disease, and without criteria of depression revealed by HAD&#xD;
      (Hospital Anxiety and Depression) scale, evaluation of fatigue will be done with the MFI 20&#xD;
      scale. Patients with a MFI 20 score ≥60/100 and corresponding to inclusion criteria will be&#xD;
      invited to participate.&#xD;
&#xD;
      After randomisation, a baseline evaluation will be done, including MFI20, Norris VAS, EORTC&#xD;
      QLQ-C30, Mattis scale, Trail Making Test, Grober and Buschke, Wisconsin Card Sorting Test ,&#xD;
      HAD scale and Marin scale.&#xD;
&#xD;
      Patients will receive, in a double blinded way, six pills a day either of dexamphetamine&#xD;
      sulfate (15 mg*2) or of placebo, during 3 months, after an initial phase of progressive&#xD;
      increasing levels of dose every 10 days, depending on tolerance.&#xD;
&#xD;
      The evaluation of fatigue, quality of life will be done every month during the 3 months of&#xD;
      treatment. The cognitive evaluation will be done at 3 months.&#xD;
&#xD;
      The main criteria of evaluation is the variation during 3 months of the MFI 20 score in non&#xD;
      progressive patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Multidimensional Fatigue inventory - MFI 20 scale score</measure>
    <time_frame>3 months</time_frame>
    <description>improvement of the MFI 20 score between the inclusion and the evaluation at 3 months in case of non progressive disease during this period of time.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>Dexamfetamine sulphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamfetamine Sulphate 5 mg Tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Aspect tablets identical to the active</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamfetamine sulphate</intervention_name>
    <description>10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.</description>
    <arm_group_label>Dexamfetamine sulphate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Patients complaining of a severe asthenia defined as a MFI 20 score ≥ 60/100&#xD;
&#xD;
          -  Patients suffering from histologically proven gliomas&#xD;
&#xD;
          -  Patients with responsive or stable disease (according to RANO criteria) for at least 3&#xD;
             months, either still on chemotherapy or only being under simple surveillance&#xD;
&#xD;
          -  stable dosage of steroids for at least 1 week&#xD;
&#xD;
          -  Time elapsed post-radiotherapy more than 3 months&#xD;
&#xD;
          -  HAD score of depression ≤8&#xD;
&#xD;
          -  Karnofsky performance index ≥ 60&#xD;
&#xD;
          -  ≥ 18 years of age&#xD;
&#xD;
          -  contraceptive measures&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
          -  Depending from the french system of health assurance&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          -  Severe aphasia or other symptoms compromising the tests execution&#xD;
&#xD;
          -  concomitant uncontrolled pathology&#xD;
&#xD;
          -  Known symptomatic or constitutional cardiovascular disease, (cardiac arrhythmia,&#xD;
             recent myocardial infarction, chest pain, history of unstable angina) and/or&#xD;
             uncontrolled hypertension, (≥ 16/10), arteriosclerosis, cardiac abnormality detected&#xD;
             at the initial cardiac echography.&#xD;
&#xD;
          -  Hyperthyroidism&#xD;
&#xD;
          -  Known hypersensitivity to dexamphetamine or related compounds&#xD;
&#xD;
          -  Glaucoma&#xD;
&#xD;
          -  Porphyria&#xD;
&#xD;
          -  Hemoglobin level of less than 10,0 g/dL&#xD;
&#xD;
          -  Alcohol or drug abuse,&#xD;
&#xD;
          -  Agitation&#xD;
&#xD;
          -  Tourette's syndrome&#xD;
&#xD;
          -  Patients who have been receiving MAO inhibitors during the past 14 days&#xD;
&#xD;
          -  Hereditary hypersensitivity to galactose, Lapp lactase deficiency or glucose-galactose&#xD;
             malabsorption syndrome&#xD;
&#xD;
          -  Hereditary hypersensitivity to saccharose, glucose-galactose malabsorption syndrome or&#xD;
             saccharase-isomaltase deficiency&#xD;
&#xD;
          -  Pregnant or lactating woman&#xD;
&#xD;
          -  Non french speaker&#xD;
&#xD;
          -  History of psychiatric disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence LAIGLE-DONADEY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florence LAIGLE-DONADEY, MD</last_name>
    <email>florence.laigle-donadey@psl.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence LAIGLE-DONADEY, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>February 9, 2015</study_first_submitted>
  <study_first_submitted_qc>February 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2015</study_first_posted>
  <last_update_submitted>September 14, 2016</last_update_submitted>
  <last_update_submitted_qc>September 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dexamfetamine sulphate</keyword>
  <keyword>severe asthenia</keyword>
  <keyword>glioma</keyword>
  <keyword>MFI-20</keyword>
  <keyword>double-blind</keyword>
  <keyword>stabilisation phase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Asthenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dextroamphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

